European CRO Evotec cashes in on strategic partnerships

By Zachary Brennan

- Last updated on GMT

Related tags Central nervous system Evotec

Evotec has had a breakthrough year in 2014
Evotec has had a breakthrough year in 2014
Contract drug developer Evotec AG has achieved multiple milestones resulting in €8m ($9.8m) in revenue thanks to its collaborations with Bayer and Janssen Pharmaceuticals.

The revenues, which will be recognised in FY 2014, were reached in Evotec’s multi-target collaboration with Bayer HealthCare in endometriosis and thanks to its partnership with Janssen for the EVT100 series for the treatment of CNS diseases.

The revenues come as Evotec is in negotiations over a $310m (€250m) strategic partnership with Sanofi​ that will look to tackle major initiatives over five years in oncology and related to Evotec’s compound library.


In its multi-target collaboration with Bayer, Evotec has reached important milestones for the transition of certain molecules into pre-clinical development for the treatment of endometriosis. These milestones were achieved under the agreement between Evotec and Bayer signed in October 2012.

The goal of this collaboration is to identify three clinical candidates within the five-year alliance. Both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis.


In its collaboration with Janssen on a NR2B subtype selective NMDA-antagonist portfolio for development against CNS (central nervous system) diseases, Evotec has reached an important validation milestone for a new, unnamed compound.

Ohio St.

On Monday, Evotec also unveiled a new relationship with the Ohio St. University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The objective of the collaboration is to develop a novel mechanism for engaging the KRas target discovered at the university using Evotec's tech platform and expertise in drug discovery and pre-clinical development.

KRas is a small GTPase (a large family of hydrolase enzymes) regulating the RAS/MAPK signalling cascade that governs cell division. Mutations in KRas are early transforming events in tumourigenesis and are highly prevalent in ancers such as lung, colon and pancreatic cancer.

Evotec previously formed a research partnership​ with Harvard to study ALS.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more